Metelimumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
History
[edit]Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
References
[edit]- ^ Sorbera LA (2004). "Metelimumab: Agent for scleroderma prop inn human anti-TGF-β1 monoclonal antibody". Drugs of the Future. 29 (11): 1081–3. doi:10.1358/dof.2004.029.11.860002.
- ^ a b Foley S (10 February 2004). "CAT may abandon skin drug after trial results disappoint".
{{cite journal}}: Cite journal requires|journal=(help) - ^ a b "Tasidotin". Genzyme. 2006. Archived from the original on 2006-09-02. Retrieved 2009-07-27.
- ^ "Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies". PR News Wire. Archived from the original on 15 July 2011.
- ^ "Cambridge Antibody, Genzyme to collaborate on human anti-TGFBeta monoclonals". Drug Discovery Online. 2 October 2000.
- ^ "CAT-192 is safe but efficacy in doubt". The Pharma Letter. 16 February 2002.
- ^ Clinical trial number NCT00043706 for "Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |